Updates on COVID-19 (including visitor restrictions and mask requirements), monkeypox and flu. See Communicable Disease Updates

Your browser is out-of-date!

Internet Explorer 11 has been retired by Microsoft as of June 15, 2022. To get the best experience on this website, we recommend using a modern browser, such as Safari, Chrome or Edge.

×

Local consolidative therapy (LCT) for selective oligometastatic cancers

Trial ID:
IRB-20-7507
Patrick W Linson, MD, MPH
The goal of this study is to learn if giving local consolidative therapy (LCT) up-front can better help to control oligometastatic disease, compared to a strategy of closely monitoring patients and waiting to give LCT at a later time point. LCT includes surgery, radiation, or other interventions.

Inclusion Criteria

Patients must:
  • Have had no more than 4 prior lines of systemic therapy administered to treat metastatic disease
  • Be 18 years of age on the day of signing informed consent
  • Have pathology confirmed diagnosis of cancer (Oligometastatic solid tumors)

Exclusion Criteria

Patients must not:
  • Have a diagnosis of active scleroderma, lupus, or other rheumatologic disease which in the opinion of the treating radiation oncologist precludes safe radiation therapy
  • Have known psychiatric or substance abuse disorders
  • Have metastatic effusion (e.g. pleural effusion or ascites)
  • Be pregnant or expecting to conceive within the projected duration of the trial at the screening visit

Additional Info

  • All treatments and physician visits will be conducted at the Scripps La Jolla site.
  • For more information, search for NCT03599765 at www.clinicaltrials.gov.

Contact Info:

  • Clinical Research Services
  • CRSLeadership@scrippshealth.org